RepliCel Life Sciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.093
- Today's High:
- $0.093
- Open Price:
- $0.093
- 52W Low:
- $0.051
- 52W High:
- $0.186
- Prev. Close:
- $0.097
- Volume:
- 1000
Company Statistics
- Market Cap.:
- $6.06 million
- Book Value:
- -0.09
- Revenue TTM:
- $353735
- Operating Margin TTM:
- -425.81%
- Gross Profit TTM:
- $353735
- Profit Margin:
- -259.87%
- Return on Assets TTM:
- -121%
- Return on Equity TTM:
- 0%
Company Profile
RepliCel Life Sciences Inc had its IPO on under the ticker symbol REPCF.
The company operates in the Healthcare sector and Biotechnology industry. RepliCel Life Sciences Inc has a staff strength of 0 employees.
Stock update
Shares of RepliCel Life Sciences Inc opened at $0.09 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.09 - $0.09, and closed at $0.09.
This is a -4.12% slip from the previous day's closing price.
A total volume of 1,000 shares were traded at the close of the day’s session.
In the last one week, shares of RepliCel Life Sciences Inc have slipped by -15.45%.
RepliCel Life Sciences Inc's Key Ratios
RepliCel Life Sciences Inc has a market cap of $6.06 million, indicating a price to book ratio of 0 and a price to sales ratio of 8.3521.
In the last 12-months RepliCel Life Sciences Inc’s revenue was $353735 with a gross profit of $353735 and an EBITDA of $-1505525. The EBITDA ratio measures RepliCel Life Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, RepliCel Life Sciences Inc’s operating margin was -425.81% while its return on assets stood at -121% with a return of equity of 0%.
In Q1, RepliCel Life Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
RepliCel Life Sciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into RepliCel Life Sciences Inc’s profitability.
RepliCel Life Sciences Inc stock is trading at a EV to sales ratio of 9.6587 and a EV to EBITDA ratio of -0.8907. Its price to sales ratio in the trailing 12-months stood at 8.3521.
RepliCel Life Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $798218.00
- Total Liabilities
- $2.07 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
RepliCel Life Sciences Inc ended 2024 with $798218.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $798218.00 while shareholder equity stood at $-5915261.00.
RepliCel Life Sciences Inc ended 2024 with $0 in deferred long-term liabilities, $2.07 million in other current liabilities, 31661019.00 in common stock, $-42974870.00 in retained earnings and $0 in goodwill. Its cash balance stood at $413025.00 and cash and short-term investments were $430275.00. The company’s total short-term debt was $0 while long-term debt stood at $40956.00.
RepliCel Life Sciences Inc’s total current assets stands at $635677.00 while long-term investments were $0 and short-term investments were $17250.00. Its net receivables were $82169.00 compared to accounts payable of $0 and inventory worth $140148.00.
In 2024, RepliCel Life Sciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, RepliCel Life Sciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.09
- 52-Week High
- $0.186
- 52-Week Low
- $0.051
- Analyst Target Price
- $
RepliCel Life Sciences Inc stock is currently trading at $0.09 per share. It touched a 52-week high of $0.186 and a 52-week low of $0.186. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.12 and 200-day moving average was $0.11 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6450.2% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About RepliCel Life Sciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. The company was founded in 2006 and is headquartered in Vancouver, Canada.